Metraipolis › archive › dc_d39b1e10bdcd

Test data exclusivity — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Test_data_exclusivity
License (as archived)
CC-BY-SA-4.0
Archived
2026-10-06T00:17:59.621Z
SHA-256 of the archived text
a30f4c31703750174f384e55ad5d79fe1e615f5ca923dab23df6fb43239bf801
Stable URL of this page
https://metraipolis.com/documento/dc_d39b1e10bdcd

How to cite

Test data exclusivity — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Test_data_exclusivity (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_d39b1e10bdcd (Metraipolis archive dc_d39b1e10bdcd, sha256 a30f4c31703750174f384e55ad5d79fe1e615f5ca923dab23df6fb43239bf801)
BibTeX
@misc{dcd39b1e10bdcd,
  title = {Test data exclusivity — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Test_data_exclusivity},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_d39b1e10bdcd; sha256 a30f4c31703750174f384e55ad5d79fe1e615f5ca923dab23df6fb43239bf801},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Test_data_exclusivity. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Test data exclusivity refers to protection of clinical trial data required to be submitted to a regulatory agency to prove safety and efficacy of a new drug, and prevention of generic drug manufacturers from relying on this data in their own applications. It provides a form of market exclusivity outside that provided by patent rights. Pharmaceutical companies argue that since test data is so expensive to produce, it is an unfair advantage to let other companies rely on that data without cost. Critics charge that it can act as a restriction to producing a generic copy; that although it would not raise prices of drugs, it would prevent prices from falling due to generic competition; and make it more costly for the poor to gain access to life-saving drugs (e.g. anti-HIV & anti-malarial medications.) Developed countries with innovative pharmaceutical industries (including the United States) have sought data exclusivity provisions in Free Trade Agreements with their trading partners, e.g. DR-CAFTA which includes such a provision. According to the European Commission: ""Data exclusivity" refers to the period during which the data of the original marketing authorisation holder relating to (pre-) clinical testing is protected. Accordingly, in relation to marketing authorisation applications submitted after 30 October 2005 for the applications filed in the framework of national procedures or 20 November 2005 for applications filed in the framework of the centralised procedure, 'data exclusivity' refers to the eight-year protection period during which generic applicant may not refer to the information of the original marketing authorisation holder and 'marketing exclusivity' refers to the ten-year period after which generic products can be placed on the market. However, in relation to marketing authorisation applications submitted before the above mentioned dates, the wording 'data exclusivity' refers to the six or ten-year protection period granted to the original marketing authorisation (MA) holder before generic applicants can file their applications for marketing authorisation." One critical issue in this regard is the issue of data exclusivity for pioneer drug companies (pharmaceutical R&D organizations). From the standpoint of economics, industries where the R&D process is costly and risky need longer exclusivity periods to realize innovation benefits, compared to those industries where innovation is easier and less costly. Some academics allege that pharmaceutical data exclusivity protection unfairly restricts the rapid public dispersal of knowledge that is supposed to be the trade-off for a grant of a patent or intellectual monopoly privilege. They allege that data exclusivity is really a form of evergreening pharmaceutical patent protection that may even restrict the capacity of governments to benefit from the granting of a compulsory license on the patents on a medicine, since the data monopoly will still prevent the marketing of generic products

Tema degli esploratori: diritto e tecnologia (deposito sistematico; ricerca «data protection»).
Fonte: Wikipedia in inglese, voce «Test data exclusivity» — https://en.wikipedia.org/wiki/Test_data_exclusivity
Wikidata Q7705761 (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q7705761
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Test_data_exclusivity?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1377828403, consultata il 2026-10-05T23:35:26.926Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 519ac48a51dd7f5ceacfd3b8e01e2ab1e526a653295feb11cddaa586e04a3f81